Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.

Article  PubMed  Google Scholar 

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease: treatment of motor symptoms in PD. Mov Disord. 2018;33(8):1248–66.

Article  CAS  PubMed  Google Scholar 

Hauser RA. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63(12):1756.

Article  PubMed  Google Scholar 

Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28(8):1064–71.

Article  CAS  PubMed  Google Scholar 

Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S2-41.

PubMed  Google Scholar 

Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196–205.

Article  PubMed  Google Scholar 

Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol. 2009;8(10):929–37.

Article  CAS  PubMed  Google Scholar 

Guide parcours de soins maladie de Parkinson [Internet]. Haute Autorité de Santé. [accessed 1 sept 2023]. Available at: https://www.has-sante.fr/jcms/c_1242645/fr/guide-parcours-de-soins-maladie-de-parkinson

Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, et al. Descriptive analysis of the French NS-Park registry: towards a nation-wide Parkinson’s disease cohort? Parkinsonism Relat Disord. 2019;64:226–34.

Article  PubMed  Google Scholar 

Clarke CE, Patel S, Ives N, Rick CE, Woolley R, Wheatley K, et al. UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria [Internet]. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson’s disease: a large pragmatic randomised controlled trial (PD REHAB). NIHR Journals Library; 2016 [accessed 18 August 2021]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK379754/

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.

Article  PubMed  Google Scholar 

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53.

Article  PubMed  Google Scholar 

Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6.

Article  CAS  PubMed  Google Scholar 

Allaire JJ, Ellis P, Gandrud C, Kuo K, Lewis BW, Owen J, et al. networkD3: D3 JavaScript Network Graphs from R [Internet]. 2017 [accessed 21 May 2024]. Available at: https://cran.r-project.org/web/packages/networkD3/index.html

Gabadinho A, Studer M, Müller N, Bürgin R, Fonta PA, Ritschard G. TraMineR: Trajectory Miner: a Sequence Analysis Toolkit [Internet]. 2024 [accessed 21 May 2024]. Available: https://cran.r-project.org/web/packages/TraMineR/index.html

Zhang Z, Sun J. Interval censoring. Stat Methods Med Res. 2010;19(1):53–70.

Article  PubMed  Google Scholar 

Anderson-Bergman C. icenReg: Regression Models for Interval Censored Data [Internet]. 2020 [accessed 6 oct 2022]. Available at: https://CRAN.R-project.org/package=icenReg

Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91(3):e189-201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Micco R, Satolli S, Siciliano M, De Mase A, Giordano A, Tedeschi G, et al. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study. Neurol Sci janv. 2022;43(1):357–64.

Article  Google Scholar 

Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O. Sleep and sleepiness in patients with Parkinson’s disease before and after dopaminergic treatment. Euro J Neurology mars. 2005;12(3):199–207.

Article  CAS  Google Scholar 

Ataide M, Franco CMR, Lins OG. Daytime sleepiness in Parkinson’s disease: perception, influence of drugs, and mood disorder. Sleep Disord. 2014;2014: 939713.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD. Development of excessive daytime sleepiness in early Parkinson disease. Neurology. 2015;85(2):162–8.

Article  PubMed  Google Scholar 

Feng F, Cai Y, Hou Y, Ou R, Jiang Z, Shang H. Excessive daytime sleepiness in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2021;85:133–40.

Article  PubMed  Google Scholar 

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484–91.

Article  CAS  PubMed  Google Scholar 

Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine agonists and their risk to induce psychotic episodes in Parkinson’s disease: a case-control study. BMC Neurol. 2009;9:23.

Article  PubMed  PubMed Central  Google Scholar 

Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev. 2008;2:6564.

Google Scholar 

Mai AS, Lee YS, Yong JH, Teo DCYJ, Wan YM, Tan EK. Treatment of apathy in Parkinson’s disease: a Bayesian network meta-analysis of randomised controlled trials. Heliyon. 2024;10(4): e26107.

Article  PubMed  PubMed Central  Google Scholar 

Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms—results of a double-blind, randomized, placebo-controlled trial. Euro J Neurol. 2015;22(10):1400–7.

Article  CAS  Google Scholar 

Tsuboi T, Satake Y, Hiraga K, Yokoi K, Hattori M, Suzuki M, et al. Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: a systematic review. NPJ Parkinsons Dis. 2022;8(1):1–21.

Article  Google Scholar 

Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, et al. Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. 2004;329(7466):593.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(10):2731–42.

Article  PubMed  PubMed Central  Google Scholar 

Orayj K, Lane E. Patterns and determinants of prescribing for Parkinson’s disease: a systematic literature review. Parkinsons Dis. 2019;2019:9237181.

PubMed  PubMed Central  Google Scholar 

Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, et al. Dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: a report of the AAN Guideline Subcommittee. Neurology. 2021;97(20):942–57.

Article  PubMed  PubMed Central  Google Scholar 

Debove I, Paschen S, Amstutz D, Cardoso F, Corvol JC, Fung VSC, et al. Management of impulse control and related disorders in Parkinson’s disease: an expert consensus. Mov Disord. 2024;39(2):235–48.

Article  PubMed  Google Scholar 

Faouzi J, Bekadar S, Artaud F, Elbaz A, Mangone G, Colliot O, et al. Machine learning-based prediction of impulse control disorders in Parkinson’s disease from clinical and genetic data. IEEE Open J Eng Med Biol. 2022;3:96–107.

Article  PubMed  Google Scholar 

Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–98.

Article  PubMed  PubMed Central  Google Scholar